fbpx
CooperVision

Multiple CooperVision Presentations Elevate Ocular Science at Academy 2024

CooperVision has unveiled its broad scientific program for the 2024 American Academy of Optometry annual meeting, helping build clinical knowledge and practice around a range of topics such as myopia management, presbyopia, dry eye, and contact lens handling. The event is expected to draw thousands of eye care professionals (ECPs), researchers, educators, and students to Indianapolis this week.

“As a longstanding partner to the global eye care community, we strongly believe in conducting and sharing research that advances how ECPs work with patients to achieve the best possible outcomes. Our scientists and study collaborators are eager to discuss several of the timeliest topics in optometry, reinforcing CooperVision’s focus on developing innovative products whose clinical advantages are complemented by robust evidence.”

Francis Erard, Vice President of Research & Development, CooperVision

A worldwide leader in myopia management, the company will spotlight multiple works relating to the efficacy of its MiSight® 1 day* contact lens1 and Paragon CRT® 100 orthokeratology contact lenses2, as well as clinical practice patterns.3

Following the debut of its clariti® 1 day multifocal with Binocular Progressive System contact lenses earlier this year, CooperVision adds to the conversation at Academy with two studies that provide ECPs with information on multifocal fit success. A comparison with a differently designed daily disposable multifocal contact lens indicates better overall vision satisfaction with the unique Binocular Progressive System technology4, while another investigation highlights patient acceptance and first fit success when moving from the original clariti® multifocal to the new 3-Add lens.5

Rounding out the scientific program are a presentation from the Centre for Ocular Research & Education (CORE) that explores how symptomatic soft contact lens wearers and non-wearers can be successfully fit with Onefit MED scleral lenses6, and another that examines the impact of lens back vertex power and material on subjective contact lens handling,7 which can be a discontinuation driver among patients, especially neophytes.

Additional information regarding Academy 2024, which runs from November 6-9, is available at https://aaopt.org/meetings/academy-2024-indianapolis/.

Click HERE for the press release.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!

* Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

__________________________________

References:

1 Arumugam B et al. Efficacy of MiSight® 1 day dual focus lenses in controlling myopia progression in Chinese children. AAO 2024 poster presentation.

2 Jung L et al. Efficacy of OrthoK in axial inhibition: A comprehensive retrospective review of real-world patient population from UC Berkeley Myopia Control Clinic. AAO 2024 poster presentation.

3 Fromstein S et al. Clinical Practice Patterns for the Initial Management of Young Myopic Patients in Canada. AAO 2024 poster presentation.

4 Sulley A et al. Patient Acceptance of Two Daily Disposable Multifocal Contact Lenses. AAO 2024 poster presentation.

5 Vega J et al. Ease of Success Refitting Habitual Multifocal Soft Lens Wearers with a New Progressive Multifocal Lens System. AAO 2024 poster presentation.

6 Fadel D et al. Evaluation of Scleral Lenses in the Management of Dry Eye Symptoms. AAO 2024 poster presentation.

7 Read M et al. The impact of lens back vertex power and material on contact lens handling. AAO 2024 poster presentation.

Featured Posts

Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read More
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read More
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read More
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read More
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more
Fighting Blindness Canada research

Gene Therapy for Wet AMD: Phase 1/2 Clinical Trial Results

A new study published in The Lancet shared results from a Phase 1/2 clinical trial testing a one-time anti-VEGF gene therapy for wet age-related macular degeneration (wet AMD).

Learn More
CooperVision

CooperVision Hosts Canadian ECPs for Innovation Tour in Costa Rica

CooperVision recently hosted an Innovation Tour for 20 eye care professionals from across Canada at its state-of-the-art, LEED® certified manufacturing facility located in San José, Costa Rica.

Read more
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions.

Read more
SightGlass Vision

Three New Peer Reviewed Papers Expand Myopia Management Evidence for SightGlass Vision Diffusion Optics Technology™

Works in BMJ Open Ophthalmology, Ophthalmic and Physiological Optics, and Translational Vision Science & Technology Focus on Efficacy, Vision, and Contrast Theory

Read more
Kappa Visibilia logos

VISIBILIA and Kappa® (BasicNet) Announce Exclusive Licensing Agreement

Visibilia and Kappa® have announced an exclusive licensing agreement for the design, production, and distribution of Kappa® eyewear.

Read more